The U.S. Food and Drug Administration has approved deflazacort,
a new treatment for Duchenne muscular dystrophy in patients 5 years and
older.
Deflazacort, developed by Marathon Pharmaceuticals LLC, is the first corticosteroid approved by the FDA to treat Ducheene
muscular dystrophy.
Marathon
plans to release the drug this year under the brand name Emflaza.
FDA approves deflazacort for muscular dystrophy patients
Alerts Sign-up